Academic Journal
Προβολή σε EDS

Establishing a New Stem Cell Crossmatch Assay to Assess the Impact of HLA-Specific Antibodies on CD34+ Stem Cells.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Establishing a New Stem Cell Crossmatch Assay to Assess the Impact of HLA-Specific Antibodies on CD34+ Stem Cells.
Συγγραφείς: Ford LB; Histocompatibility and Immunogenetics Laboratory, Liverpool Clinical Laboratories, Royal Liverpool University Hospital, Liverpool, UK., Irvine M; Transplantation Laboratory, Manchester University NHS Foundation Trust, Manchester, UK., Lee H; Transplantation Laboratory, Manchester University NHS Foundation Trust, Manchester, UK., Poulton KV; Transplantation Laboratory, Manchester University NHS Foundation Trust, Manchester, UK.
Πηγή: HLA [HLA] 2026 Jun; Vol. 107 (6), pp. e70782.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wiley Blackwell Country of Publication: England NLM ID: 101675570 Publication Model: Print Cited Medium: Internet ISSN: 2059-2310 (Electronic) Linking ISSN: 20592302 NLM ISO Abbreviation: HLA Subsets: MEDLINE
Imprint Name(s): Original Publication: Oxford : Wiley Blackwell, [2016]-
Ιατρικοί όροι (MeSH): Antigens, CD34*/immunology , Antigens, CD34*/metabolism , Histocompatibility Testing*/methods , HLA Antigens*/immunology , Isoantibodies*/immunology , Isoantibodies*/blood , Hematopoietic Stem Cells*/immunology , Hematopoietic Stem Cell Transplantation*, Flow Cytometry/methods ; Humans ; Transplantation, Homologous
Περίληψη: Mismatched allogeneic haematopoietic stem cell transplants (HSCT) are complicated by the presence of pre-existing HLA-specific antibodies targeting the mismatched HLA antigens (DSAs). Data indicates that the presence of DSAs pre-transplant, termed HLA incompatible HSCT, is associated with inferior outcomes and graft failure. Whilst studies acknowledge that DSAs should be avoided there is limited information regarding the impact of specific DSAs and their levels on HSCT outcomes. There is also a recognised lack of knowledge and methods which allow the immunological risk of HLA incompatible HSCT to be defined, with a large volume of data being extrapolated from solid organ transplant data. We have established a stem cell specific flow cytometry crossmatch (SC-FCXM) for the in vitro assessment of the binding capacity of HLA-specific antibodies to CD34+ stem cells. A library of HLA typed expanded human CD34+ progenitor cells from cord blood (CB-CD34+) was generated and used to assess HLA-specific antibody binding of 86 serum samples from the National External Quality Assurance Scheme (NEQAS) Histocompatibility and Immunogenetics crossmatching 2B external proficiency testing scheme issued between 2023 and 2025. Sera were analysed using LABScreen Single Antigen (LSSAg) Class I and II and donor specific HLA antibodies (DSAs) were identified for each CB-CD34+ and serum combination. A range of DSAs targeting single HLA antigens, plus multiple HLA-specific Class I, Class II or a combination of Class I and II antibodies based on mean fluorescence intensity (MFI) was examined. The impact of increasing DSA MFI on SC-FCXM reactivity was determined by correlation and regression studies comparing cumulative peak LSSAg MFI versus median fluorescence intensity of anti-human IgG APC as determined by the SC-FCXM (APC Median SC-FCXM). As LSSAg MFI of DSAs targeting HLA-A (p = 0.0001), -B (p = 0.0001) and -DRB1 (p = 0.0155) increased, there was significant correlation with APC Median SC-FCXM, but no correlation (p > 0.05) between LSSAg MFI and APC Median SC-FCXM for HLA-C, -DQB1, -DQA1 or -DPB1. A significant correlation (p ≤ 0.05) was observed for multiple HLA Class I (p = 0.0005), Class II (p = 0.0001), plus combinations of Class I and II DSAs (p = 0.0013) between combined LSSAg MFI and APC Median SC-FCXM. The extrapolation of this preliminary data has provided an indication of which DSAs and their levels (as determined by LSSAg MFI) cause FCXM reactivity against CD34+ stem cells, which could prove to be relevant in HLA incompatible HSCT. However, the assay currently remains a proof-of-concept and further work is required to establish clinical correlation of the results to patient outcomes.
(© 2026 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
References: A. M. Little, A. Akbarzad‐Yousefi, A. Anand, et al., “BSHI Guideline: HLA Matching and Donor Selection for Haematopoietic Progenitor Cell Transplantation,” International Journal of Immunogenetics 48, no. 2 (2021): 75–109.
J. A. Snowden, I. Sanchez‐Ortega, S. Corbacioglu, et al., “Indications for Haematopoietic Cell Transplantation for Haematological Diseases, Solid Tumours and Immune Disorders: Current Practice in Europe, 2022,” Bone Marrow Transplantation 57, no. 8 (2022): 1217–1239.
D. S. Mangum and E. Caywood, “A Clinician's Guide to HLA Matching in Allogeneic Hematopoietic Stem Cell Transplant,” Human Immunology 83, no. 10 (2022): 687–694.
J. R. Passweg, H. Baldomero, P. Bader, et al., “Use of Haploidentical Stem Cell Transplantation Continues to Increase: The 2015 European Society for Blood and Marrow Transplant Activity Survey Report,” Bone Marrow Transplantation 52, no. 6 (2017): 811–817.
D. M. Ponce, I. Politikos, A. Alousi, et al., “Guidelines for the Prevention and Management of Graft‐Versus‐Host Disease After Cord Blood Transplantation,” Transplantation and Cellular Therapy 27, no. 7 (2021): 540–544.
A. Brand, I. N. Doxiadis, and D. L. Roelen, “On the Role of HLA Antibodies in Hematopoietic Stem Cell Transplantation,” Tissue Antigens 81, no. 1 (2013): 1–11.
M. Liu, Z. Kang, and H. Zhang, “Impacts of Donor‐Specific Anti‐HLA Antibodies on Post‐Transplant Clinical Outcomes in Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta‐Analysis,” Transplant Immunology 92 (2025): 102275.
M. Osada, H. Yamamoto, O. Watanabe, et al., “Lymphocyte Crossmatch Testing or Donor HLA‐DP and ‐DQ Allele Typing Effectiveness in Single Cord Blood Transplantation for Patients With Anti‐HLA Antibodies Other Than Against HLA‐A, ‐B, ‐C, and ‐DRB1,” Transplantation and Cellular Therapy 30, no. 7 (2024): e614–e691.
S. O. Ciurea, F. Aung, M. de Lima, et al., “Anti‐HLA Antibodies and Graft Rejection in Hematopoietic Stem Cell Transplantation,” Blood 116, no. 21 (2010): 519.
D. E. Gladstone and M. P. Bettinotti, “HLA Donor‐Specific Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation: Challenges and Opportunities,” Hematology. American Society of Hematology. Education Program 2017, no. 1 (2017): 645–650.
B. D. Tait, C. Susal, H. M. Gebel, et al., “Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non‐HLA Antibodies in Transplantation,” Transplantation 95, no. 1 (2013): 19–47.
B. G. Park, Y. Park, B. S. Kim, Y. S. Kim, and H. S. Kim, “False Positive Class II HLA Antibody Reaction due to Antibodies Against Denatured HLA Might Differ Between Assays: One Lambda vs. Immucor,” Annals of Laboratory Medicine 40, no. 5 (2020): 424–427.
P. A. Flynn, S. Fernando, J. E. Worthington, and K. V. Poulton, “Predicting Flow Cytometry Crossmatch Results From Single‐Antigen Bead Testing,” International Journal of Immunogenetics 51, no. 2 (2024): 93–99.
S. R. Oguz, A. Sinangil, S. Barlas, et al., “Correlation of Luminex‐Based Single Antigen Based Results With Complement‐Dependent Cytotoxicity Crossmatch and Flow Cytometry Crossmatch Results: A Single‐Center Experience From Istanbul,” Transplantation Proceedings 55, no. 2 (2023): 303–308.
S. Vaidya, D. Partlow, B. Susskind, M. Noor, T. Barnes, and K. Gugliuzza, “Prediction of Crossmatch Outcome of Highly Sensitized Patients by Single and/or Multiple Antigen Bead Luminex Assay,” Transplantation 82, no. 11 (2006): 1524–1528.
N. El‐Awar, P. I. Terasaki, A. Nquyen, et al., “Epitopes of Human Leukocyte Antigen Class I Antibodies Found in Sera of Normal Healthy Males and Cord Blood,” Human Immunology 70, no. 10 (2009): 844–853.
P. C. Grenzi, R. de Marco, R. Z. Silva, E. F. Campos, and M. Gerbase‐DeLima, “Antibodies Against Denatured HLA Class II Molecules Detected in Luminex‐Single Antigen Assay,” Human Immunology 74, no. 10 (2013): 1300–1303.
L. E. Morales‐Buenrostro, P. I. Terasaki, L. A. Marino‐Vazquez, J. H. Lee, N. El‐Awar, and J. Alberu, ““Natural” Human Leukocyte Antigen Antibodies Found in Nonalloimmunized Healthy Males,” Transplantation 86, no. 8 (2008): 1111–1115.
J. Visentin, T. Bachelet, O. Aubert, et al., “Reassessment of the Clinical Impact of Preformed Donor‐Specific Anti‐HLA‐Cw Antibodies in Kidney Transplantation,” American Journal of Transplantation 20, no. 5 (2020): 1365–1374.
S. O. Ciurea, P. F. Thall, D. R. Milton, et al., “Complement‐Binding Donor‐Specific Anti‐HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation,” Biology of Blood and Marrow Transplantation 21, no. 8 (2015): 1392–1398.
R. Battle, D. Pritchard, S. Peacock, et al., “BSHI and BTS UK Guideline on the Detection of Alloantibodies in Solid Organ (And Islet) Transplantation,” International Journal of Immunogenetics 50, no. Suppl 2 (2023): 3–63.
M. P. Bettinotti, “Evolution of HLA Testing for Hematopoietic Stem Cell Transplantation: Importance of the Candidate's Antibody Profile for Donor Selection,” Human Immunology 83, no. 10 (2022): 721–729.
M. P. Bettinotti, D. P. Lucas, G. Ghiaur, A. M. Jackson, and D. E. Gladstone, “HLA Expression on CD34+ Stem Cells: Is a Flow Cytometric Crossmatch a Good Gatekeeper for Mismatched Hematopoietic Cell Transplantion?,” Human Immunology 79 (2018): 35.
M. P. Bettinotti, D. P. Lucas, G. Ghiaur, A. M. Jackson, and D. E. Gladstone, “HLA‐Class I and II Antigens Are Expressed in CD34+ Cells: Implications for HLA Mismatched Bone Marrow Transplantation (BMT),” Biology of Blood and Marrow Transplantation 24, no. 3 (2018): S420–S421.
D. R. Sutherland, L. Anderson, M. Keeney, R. Nayar, and I. Chin‐Yee, “The ISHAGE Guidelines for CD34+ Cell Determination by Flow Cytometry. International Society of Hematotherapy and Graft Engineering,” Journal of Hematotherapy 5, no. 3 (1996): 213–226.
R. S. Liwski, A. L. Greenshields, C. Murphey, R. A. Bray, and H. M. Gebel, “It's About Time: The Development and Validation of a Rapid Optimized Single Antigen Bead (ROB) Assay Protocol for LABScreen,” Human Immunology 78, no. 7–8 (2017): 489–499.
R. S. Liwski, A. L. Greenshields, D. M. Conrad, et al., “Rapid Optimized Flow Cytometric Crossmatch (FCXM) Assays: The Halifax and Halifaster Protocols,” Human Immunology 79, no. 1 (2018): 28–38.
A. R. Tambur and C. Schinstock, “Clinical Utility of Serial Serum Dilutions for HLA Antibody Interpretation,” HLA 100, no. 5 (2022): 457–468.
M. Turner, S. Leslie, N. G. Martin, et al., “Toward the Development of a Global Induced Pluripotent Stem Cell Library,” Cell Stem Cell 13, no. 4 (2013): 382–384.
C. J. Taylor, S. Peacock, A. N. Chaudhry, J. A. Bradley, and E. M. Bolton, “Generating an iPSC Bank for HLA‐Matched Tissue Transplantation Based on Known Donor and Recipient HLA Types,” Cell Stem Cell 11, no. 2 (2012): 147–152.
PromoCell GmbH, “Human CD34+ Progenitor Cells (hCD34+‐CB),” (2025), https://promocell.com/uk_en/human‐cd34‐progenitor‐cells‐hcd34‐cb.html.
Contributed Indexing: Keywords: DSAs; HLA; HSCT; antibodies; crossmatch; flow cytometry
Substance Nomenclature: 0 (Antigens, CD34)
0 (HLA Antigens)
0 (Isoantibodies)
Entry Date(s): Date Created: 20260618 Date Completed: 20260618 Latest Revision: 20260618
Update Code: 20260618
DOI: 10.1111/tan.70782
PMID: 42310992
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:2059-2310
DOI:10.1111/tan.70782